RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models - PubMed (original) (raw)

. 2010 Jul 1;70(13):5518-27.

doi: 10.1158/0008-5472.CAN-10-0646. Epub 2010 Jun 15.

Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley Kolis, Sylvia Zhao, Richard Lee, Joseph F Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su

Affiliations

• PMID: 20551065
• DOI: 10.1158/0008-5472.CAN-10-0646

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

Hong Yang et al. Cancer Res. 2010.

Erratum in

• Cancer Res. 2010 Nov 15;70(22):9527

Abstract

The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical testing. Here, we report a preclinical characterization of the antitumor activity of RG7204 using established in vitro and in vivo models of malignant melanoma. RG7204 potently inhibited proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAF(V600E) or other mutant BRAF proteins altered at codon 600. In contrast, RG7204 lacked activity in cell lines that express wild-type BRAF or non-V600 mutations. In several tumor xenograft models of BRAF(V600E)-expressing melanoma, we found that RG7204 treatment caused partial or complete tumor regressions and improved animal survival, in a dose-dependent manner. There was no toxicity observed in any dose group in any of the in vivo models tested. Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring the mutant BRAF(V600E) gene.

Copyright 2010 AACR.

PubMed Disclaimer

Similar articles

• Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
  Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Yang H, et al. Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16. Cancer Res. 2012. PMID: 22180495
• The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
  Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE. Jenkins MH, et al. Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16. Matrix Biol. 2015. PMID: 25989506 Free PMC article.
• Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
  Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M. Hoeflich KP, et al. Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10. Cancer Res. 2009. PMID: 19276360
• PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
  Smalley KS. Smalley KS. Curr Opin Investig Drugs. 2010 Jun;11(6):699-706. Curr Opin Investig Drugs. 2010. PMID: 20496265 Review.
• Vemurafenib.
  Garbe C, Abusaif S, Eigentler TK. Garbe C, et al. Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Recent Results Cancer Res. 2014. PMID: 24756795 Review.

Cited by

• Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
  Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA. Gentilcore G, et al. BMC Cancer. 2013 Jan 14;13:17. doi: 10.1186/1471-2407-13-17. BMC Cancer. 2013. PMID: 23317446 Free PMC article.
• Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
  Onoprienko A, Bartl T, Grimm C, Concin N, Polterauer S. Onoprienko A, et al. Cancers (Basel). 2024 Sep 26;16(19):3268. doi: 10.3390/cancers16193268. Cancers (Basel). 2024. PMID: 39409889 Free PMC article. Review.
• PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
  Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. Lee JT, et al. Pigment Cell Melanoma Res. 2010 Dec;23(6):820-7. doi: 10.1111/j.1755-148X.2010.00763.x. Pigment Cell Melanoma Res. 2010. PMID: 20973932 Free PMC article.
• Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
  Beloueche-Babari M, Jamin Y, Arunan V, Walker-Samuel S, Revill M, Smith PD, Halliday J, Waterton JC, Barjat H, Workman P, Leach MO, Robinson SP. Beloueche-Babari M, et al. Br J Cancer. 2013 Sep 17;109(6):1562-9. doi: 10.1038/bjc.2013.456. Epub 2013 Aug 13. Br J Cancer. 2013. PMID: 23942066 Free PMC article.
• Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
  Antonello ZA, Nucera C. Antonello ZA, et al. Oncogene. 2014 Nov 20;33(47):5397-404. doi: 10.1038/onc.2013.544. Epub 2013 Dec 23. Oncogene. 2014. PMID: 24362526 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal